MSC Exosomes for Spinal Cord Injury | BioRegenEx

Spinal cord injury (SCI) results in permanent neurological deficits in over 300,000 Americans, with 17,000 new cases each year. MSC-derived exosomes are being investigated for their ability to reduce secondary injury cascades, promote axonal regeneration, and modulate the post-injury inflammatory environment. BioRegenEx supplies FDA-registered, research-grade MSC exosomes to licensed physicians and neurorehabilitation researchers.

The Two-Phase Injury Problem

Spinal cord injury occurs in two phases. The primary mechanical injury — compression, contusion, or transection — causes immediate tissue destruction. The secondary injury phase, unfolding over hours to weeks, involves inflammation, ischemia, glutamate excitotoxicity, oxidative stress, and programmed cell death that dramatically expands the damage zone.

MSC-derived exosomes are most studied for their impact on this secondary injury cascade. By delivering neuroprotective factors, anti-apoptotic signals, and immunomodulatory cargo, they may limit the spread of damage and create conditions more favorable to regeneration.

What the Research Shows

Reducing Secondary Injury

A 2022 study in Journal of Neurotrauma demonstrated that systemically administered MSC exosomes, delivered within 24 hours of SCI in a rat contusion model, significantly reduced lesion volume, macrophage infiltration, and cavity formation at 8 weeks. Functional recovery on the BBB locomotor scale was measurably improved.

Axonal Regeneration

Research published in Biomaterials found that MSC exosomes loaded with miR-133b promoted axonal regeneration and motor neuron survival after SCI. The exosomes were incorporated into hydrogel scaffolds for sustained local delivery at the injury site.

Inflammation Modulation

Post-SCI inflammation involves a complex interplay of microglia, macrophages, neutrophils, and T-cells. Studies show MSC exosomes shift the macrophage phenotype from M1 (pro-inflammatory) to M2 (pro-repair) within the injury site, reducing TNF-α, IL-1β, and IL-6 while increasing anti-inflammatory IL-10.

Exosomal Cargo Relevant to SCI

• miR-133b: Promotes axonal growth and motor neuron survival
• BDNF (Brain-Derived Neurotrophic Factor): Supports neuronal survival and plasticity
• VEGF: Promotes angiogenesis and vascular repair at injury site
• HSP70: Anti-apoptotic, protects neurons from heat shock and oxidative stress
• miR-21: Reduces PTEN expression, activating pro-survival PI3K/Akt pathway

Important Regulatory Notice

MSC-derived exosomes are not FDA-approved treatments for spinal cord injury. All clinical use must occur under physician supervision per applicable FDA guidance. Supplied for research and physician-administered use only.

Physician Access

BioRegenEx provides research-grade MSC exosomes to licensed physicians and SCI researchers with rigorous quality characterization.

Apply for Physician Access →